ASX: EIQ RELEASE   **26 JULY, 2022**

S708A CLEANSING NOTICE

Sydney: AI & Medical Technology company Echo IQ (the **Company**) (ASX:EIQ) has issued 300,000 fully paid ordinary shares (**Shares**) on 25 July 2022 to an employee of the Company as a bonus for their contribution in helping facilitate the sale of Prometheus Information Pty. Limited (a previous wholly owned subsidiary of the Company).

The shares have been issued at a price of $0.104, being the 7-day average closing price to the date the sale was completed (July 1, 2022).

The shares will be subject to a voluntary escrow period of 6 months from the date of issue.

The Shares are part of a class of securities quoted on the Australian Securities Exchange Limited (ASX).

The Company gives this notice pursuant to Section 708A(5)(e) of the Corporations Act 2001. The Shares were issued without disclosure to the investors under Part 6D.2, in reliance on Section 708A(5) of the Corporations Act 2001. The Company, as at the date of this notice, has complied with:

i)   the provisions of Chapter 2M of the Corporations Act 2001; and
ii)   Section 674 of the Corporations Act 2001.

There is no excluded information as at the date of this notice, for the purposes of Sections 708A(7) and (8) of the Corporations Act 2001.

-ENDS-

Authorised for release by the Board of Directors of Echo IQ Limited.

Media enquiries:
Philip Woolff, Chief Operating Officer
Philip.woolff@echoiq.ai / +61 (0)490 030 620 / marketing@echoiq.ai

Investor enquiries:
Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / +61 (0) 481 339 512 / Investor@HoustonWeHave.ai

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology, Health Insurance and Defence. The company is based in Sydney, Australia.

info@echoiq.ai
+61 2 9159 3719

404/309 George St
Sydney NSW 2000

www.echoiq.ai
ABN 48 142 901 353